Table 2.
Primary and secondary end points at week 12 for brodalumab compared to placebo and ustekinumab
Disclaimer: these data were tabulated from independent studies that were not conducted in a head-to-head manner
| End point | Study | Brodalumab 210 mg | Brodalumab 140 mg | Placebo | Ustekinumab 45 mg or 90 mg |
|---|---|---|---|---|---|
| PASI 75 | AMAGINE-1, % (no./total), 95% CI | 83.3%† (185/222), 78–88 | 60.3%† (132/219), 54–67 | 2.7% (6/220), 1–6 | – |
| AMAGINE-2, % (no./total), 95% CI | 86.3%†, ¶ (528/612), 83–89 | 66.6%†, ¶ (406/610), 63–70 | 8.1% (25/309), 5–12 | 70% (210/300), 65–75 | |
| AMAGINE-3, % (no./total), 95% CI | 85.1%†, * (531/624), 82–88 | 69.2%†, ¶ (396/629), 65–73 | 6% (19/315), (4–9 | 69.3% (217/313), 64–74 | |
| PASI 90 | AMAGINE-1, % (no./total), 95% CI | 70.3%† (156/222), 64–76 | 42.5%† (93/219), 36–49 | 0.9% (2/220), 0–3 | – |
| AMAGINE-2, % (no./total), 95% CI | 69.9%†, * (428/612), N/A | 49.0%†, ¶ (299/610), N/A | 1.9% (6/309), N/A | 47.0% (141/300), N/A | |
| AMAGINE-3, % (no./total), 95% CI | 68.9%†, * (430/624), N/A | 52.0%†, ¶ (327/629), N/A | 2.9% (9/315), N/A | 47.9% (150/313), N/A | |
| PASI 100 | AMAGINE-1, % (no./total), 95% CI | 41.9%† (93/222), 36–49 | 23.3%† (51/219), 18–30 | 0.5% (1/220), 0–3 | – |
| AMAGINE-2, % (no./total), 95% CI | 44.4%†, * (272/612), 41–49 | 25.7%†, ¶ (157/610), 22–29 | 0.6% (2/309), 0–2 | 21.7% (65/300), 17–27 | |
| AMAGINE-3, % (no./total), 95% CI | 36.7%†, * (229/624), 33–41 | 27%†, * (170/629), 24–31 | 0.3% (1/315), 0–2 | 18.5% (58/313), 14–23 | |
| sPGA 0/1 | AMAGINE-1, % (no./total), 95% CI | 75.7%† (168/222), 70–81 | 53.9%† (118/219), 47–61 | 1.4% (3/220), 0–4 | – |
| AMAGINE-2, % (no./total), 95% CI | 78.6%†, * (481/612), 75–82 | 58.0%†, ¶ (354/610), 54–62 | 4% (12/309), 2–7 | 61% (183/300), 55–67 | |
| AMAGINE-3, % (no./total), 95% CI | 79.6%†, * (497/624), 76–83 | 59.9%†, ¶ (377/629), 56–64 | 4.1% (13/315), 2–7 | 57.2% (179/313), 52–63 | |
| PSI Response | AMAGINE-1, % (no./total), 95% CI | 60.8%† (135/222), 54–67 | 53.0%† (116/219), 46–60 | 4.1% (9/220), 2–8 | – |
| AMAGINE-2, % (no./total), 95% CI | 67.6%† (414/612), 64–71 | 51.5%a (314/610), 47–56 | 6.8% (21/309), 4– 0 | 55.3% (166/300), 50–61 | |
| AMAGINE-3, % (no./total), 95% CI | 61.2%† (382/624), 57–65 | 53.4%† (336/629), 49–57 | 6.3% (17/315), 4–10 | 51.8% (162/313), 46–57 |
sPGA static Physician Global Assessment, PASI Psoriasis Area and Severity Index, PSI Psoriasis Symptom Inventory, CI confidence interval
* P < 0.01 for the comparison with ustekinumab
† P < 0.001 for the comparison with placebo
¶ P > 0.05 for the comparison with ustekinumab